The global shingles vaccine market size was valued at 2.99 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 9.9% from 2021 to 2028. The increased risk of developing shingles, especially in adults aged 60 and above, and improvement in healthcare policies in developed countries are factors expected to fuel the market growth. According to the CDC estimates, around one out of three individuals in the U.S. will develop shingles in their lifetime. Vaccination is recommended in major countries such as the U.S. Canada, the U.K., Italy, Germany, Australia, New Zealand, and South Korea. In March 2021, the CDC released guidelines related to shingles vaccination during the COVID-19 pandemic and designated it as an essential preventive care service.
The shift towards novel recombinant vaccines, coupled with their high prices, is anticipated to propel market growth over the forecast period. Moreover, the U.S. Advisory Committee on Immunization Practices has recommended vaccination against shingles in adults aged 60 and above since 2006. Whereas, in January 2018, the CDC recommended Shingrix over Zostavax to prevent Shingles owing to the high efficacy of the vaccine. Similarly, Canada, Australia, and some European countries also recommend vaccination to reduce the disease burden.
The increasing cases of herpes zoster worldwide are expected to increase vaccine uptake in the coming years. The incidence of herpes zoster is estimated from 3 to 5 per 1,000 individuals per year and it increases with age. According to a study conducted in Germany, the estimated annual incidence of zoster is 5.79 cases per 1,000 population. The high risk of herpes zoster is expected to increase the adoption of shingles vaccines.
Moreover, the inclusion of shingles vaccines in national immunization programs of several countries is anticipated to boost market growth. For instance, in Australia, vaccination against shingles is funded under the National Immunization Program for adults aged 70 to 79 years, because people in this age group have a higher risk of developing herpes zoster and are expected to benefit the most from vaccination. Similarly, other countries such as the U.S., the U.K., and Italy have included shingles vaccination in their national immunization program to reduce the disease burden.
The medical cost burden of herpes zoster is increasing every year with the rising incidence of disease globally. The current treatments can only shorten the duration and lessen symptoms. To reduce the treatment cost burden of the healthcare system and the incidence of shingles, government regulatory bodies recommend vaccination against the disease.
Moreover, the cost-effectiveness of vaccines against herpes zoster compared to the treatment of shingles is anticipated to drive the uptake of vaccines globally. The cost of vaccination for one eligible adult ranges between USD 150 to USD 300 in the U.S. According to an estimate published in ResearchGate GmbH, the total annual medical care cost burden of Herpes zoster in the U.S. was over USD 1 billion.
Shingrix held the largest share of more than 90.0% in 2020 owing to the high efficacy of the vaccine with no serious events associated with it. Moreover, Shingrix is expected to grow at the highest rate over the forecast period. The growth of the segment can be attributed to the increasing awareness regarding the disease and approval of Shingrix vaccines in various regions. For instance, China's National Medical Products Administration has approved Shingrix in May 2019 to prevent shingles.
SKYZoster is expected to grow at a significant CAGR over the forecast period owing to the recommendation of SKYZoster in South Korea, cost-effectiveness compared to Zostavax, and inclusion in immunization programs of some provinces in South Korea. Furthermore, ongoing clinical trials of SKYZoster for approval and commercialization overseas are anticipated to propel the market growth over the forecast years.
The recombinant vaccine segment held the largest share of over 90.0% in 2020 owing to the high adoption of Shingrix in North America and the European region and the high efficacy of the recombinant vaccine to prevent disease in the adult population. According to the CDC, two doses of Shingrix are more than 90% effective at preventing shingles in adults of age 50 and older.
The live attenuated vaccine segment is expected to grow over the forecast period owing to the rising awareness regarding the disease and increasing adoption of vaccination in developing countries. However, the limitation of live attenuated vaccines in immune-compromised adults is negatively impacting the market uptake of live attenuated vaccines. However, the approval of SK Bioscience’s vaccine SKYZoster is anticipated to drive the segment over the forecast period.
North America grabbed the largest share of over 80.0% in 2020. The presence of major players in North America, favorable reimbursement policies, and high vaccine uptake are major factors driving the regional market. Vaccine uptake in the U.S. is around 35% and is more than 20% of the eligible population in Canada. Moreover, high awareness level among people and recommendation of vaccination against the disease in the region are some factors responsible for the market growth over the forecast period. The U.S. and Canada recommend Shingrix over Zostavax to prevent shingles in the aged population due to the high efficacy of Shingrix.
Asia Pacific is expected to expand at the fastest growth rate over the forecast period due to the increasing disposable income in the region, improvement in the healthcare policies, and a large population base having a high risk of developing the disease. Moreover, the highly unmet medical needs in low- and middle-income countries in the Asia Pacific are expected to propel the market growth during the forecast period. Moreover, approval of Shingrix in several Asian countries is anticipated to fuel the market growth.
Key players are adopting strategies such as product enhancements and regional expansion to attain a greater market share. For instance, in July 2021, GlaxoSmithKline plc. received FDA approval for Shingrix vaccines in adults aged 18 years and older. The vaccine is approved for adults who are or will be at increased risk for immunosuppression and immunodeficiency. Some prominent players in the global shingles vaccine market include:
GlaxoSmithKline plc.
Merck & Co., Inc.
SK chemicals
Green Cross Corp
Geneone Life Science
Vaccitech
CanSinoBIO
Report Attribute |
Details |
Market size value in 2021 |
USD 2.78 billion |
Revenue forecast in 2028 |
USD 6.35 billion |
Growth Rate |
CAGR of 9.9% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2017 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, vaccine type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Japan; China; Australia; South Korea; Brazil; Mexico; South Africa |
Key companies profiled |
GlaxoSmithKline plc.; Merck & Co., Inc.; SK chemicals; Green Cross Corp; CanSinoBIO |
Customization scope |
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail of customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global shingles vaccine market report on the basis of product, vaccine type, and region:
Product Outlook (Revenue, USD Million, 2017 - 2028)
Shingrix
Zostavax
SKYZoster
Vaccine Type Outlook (Revenue, USD Million, 2017 - 2028)
Recombinant Vaccine
Live Attenuated Vaccine
Regional Outlook (Revenue, USD Million, 2017 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
Japan
China
Australia
South Korea
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
b. The shingles vaccine market size was estimated at USD 2.99 billion in 2020 and is expected to reach USD 2.78 billion in 2021.
b. The shingles vaccine market is expected to grow at a compound annual growth rate of 9.9% from 2021 to 2028 to reach USD 6.35 billion by 2028.
b. Shingrix vaccine dominated the shingles vaccine market with a share of 91.86% in 2020. This is attributable to high efficacy and inclusion of the vaccine in national immunization programs of various countries.
b. Some key players operating in the shingles vaccine market include GlaxoSmithKline plc.; Merck & Co., Inc.; and SK chemicals, Green Cross Corp, Geneone Life Science, and Vaccitech.
b. Key factors that are driving the shingles vaccine market growth include increased risk of developing shingles especially in adults aged 60 & above and high adoption of vaccines in developed and developing countries.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.